STX 241
Alternative Names: PFL-241; PFL-241/STX-241; STX-241Latest Information Update: 18 Oct 2023
At a glance
- Originator Pierre Fabre; Scorpion Therapeutics
- Developer Scorpion Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 13 Oct 2023 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer released by Scorpion Therapeutics
- 11 Oct 2023 Pharmacodynamics data from a preclinical studies in Non-small cell lung cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 10 Oct 2023 Scorpion Therapeutics plans clinical trial for Non-small cell lung cancer in 2023